IP Library Granted Patent US 8,778,648
Granted Patent B2
US 8,778,648 · App. 13/072,123 · Granted Jul 15, 2014

Enzymes for reduced immunological stress

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,778,648
App. No.
13/072,123
Granted
Jul 15, 2014
Kind
B2
Abstract

Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provided, as are methods using such compositions. The compositions include animal feed compositions, liquid compositions other than animal feed, and solid compositions other than animal feed.

Claims (20)

1. A composition suitable for oral administration to an animal comprising an immune stress-reducing enzyme in an orally acceptable carrier, wherein said composition is selected from the group consisting of:

(i) an animal/feed comprising at least 20 IU of said immune stress-reducing enzyme/kg feed;

(ii) a liquid composition other than an animal feed comprising at least 40,000 IU of said immune stress-reducing enzyme/L; and

(iii) a solid composition other than an animal feed comprising at least 40,000 IU of said immune stress-reducing enzyme/kg,

wherein said immune stress-reducing enzyme is selected from the group consisting of α-1,6-mannosidase, α-1,2-mannosidase, α-1,3-mannosidase, and endo-α-1,6-D-mannanase.

2. The composition of claim 1 , wherein said composition is an animal feed comprising at least 20 of said immune stress-reducing enzyme/kg feed.

3. The composition of claim 1 , wherein said composition is a liquid composition other than an animal feed comprising at least 40,000:EU of said immune stress-reducing enzyme/L.

4. The composition of claim 1 , wherein said composition is a solid composition other than an animal feed comprising at least 40,000 IU of said immune stress-reducing enzyme/kg.

5. The composition of claim 1 , wherein the composition is a solid composition other than an animal feed comprising at least 80,000 TU of said immune stress-reducing enzyme/kg.

6. The composition of claim 1 , wherein the composition is a solid composition other than an animal feed comprising at least 160,000 IU of said immune stress-reducing enzyme/kg.

7. The composition of claim 1 , wherein the composition is an animal feed that comprises an ingredient that induces an immune response in the animal and wherein said immune stress-reducing enzyme degrades said ingredient.

8. The composition of claim 7 , wherein said ingredient is a non-pathogenic molecule that displays a molecular pattern that is recognized by the animal's innate immune system, and that is degraded by said immune stress reducing enzyme.

9. The composition of claim 7 , wherein said ingredient is an antigen displayed by a pathogenic microorganism.

10. A method of improving animal growth performance and/or reducing immune stress in an animal, comprising orally administering to said animal a composition according to claim 1 .

11. The method of claim 10 , wherein said animal is administered an ingredient that induces an immune response in the animal and wherein said immune stress reducing enzyme degrades said ingredient.

12. The method of claim 11 , wherein said ingredient and said immune stress-reducing enzyme are administered in the same composition.

13. The method of claim 12 , wherein said composition is an animal feed.

14. The method of claim 11 , wherein said ingredient is a non-pathogenic molecule that displays a molecular pattern that is recognized by the animal's innate immune system, and that is degraded by said immune stress reducing enzyme.

15. The method of claim 11 , wherein said ingredient is an antigen displayed by a pathogenic microorganism.

16. A method of preventing or treating infection associated with a pathogenic microorganism that displays an antigen, comprising orally administering to an animal in need thereof a composition according to claim 1 , wherein said immune stress-reducing enzyme degrades said antigen.

Assignments (4)
ASSIGNMENT OF SECURITY INTEREST IN PATENT RIGHTS, RECORDED ON AUGUST 3, 2020, AT REEL/FRAME 053388/0967 Recorded Dec 3, 2025
From: GOLDMAN SACHS BANK USA, AS RETIRING COLLATERAL AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT
Reel/Frame 073816/0021 →
SECURITY INTEREST Recorded Aug 3, 2020
From: ELANCO US INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 053388/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2018
From: ELI LILLY AND COMPANY
To: ELANCO US INC.
Reel/Frame 044702/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2012
From: CHEMGEN CORP.
To: ELI LILLY AND COMPANY
Reel/Frame 028223/0729 →